<DOC>
	<DOCNO>NCT00652366</DOCNO>
	<brief_summary>This study compare efficacy safety escalate versus standard dose rash Tarceva , combination gemcitabine , patient metastatic pancreatic cancer . During 4 week run-in period , patient receive Tarceva 100mg/day po plus gemcitabine 1000mg/m2 iv day 1 , 8,15 22 . After 4 week , patient develop rash , develop grade 1 rash , randomize one 2 group . Group 1 receive start dose Tarceva 150mg po daily , increased step 50mg every 2 week maximum 250mg/day po , development grade 2 rash dose-limiting toxicity . Group 2 continue receive Tarceva 100mg/day po . All patient continue receive gemcitabine 1000mg/m2 iv day 1 , 8 15 4 week cycle . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Dose-Escalation Rash Study Tarceva ( Erlotinib ) Plus Gemcitabine Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; histologically cytologically confirm pancreatic cancer measurable nonmeasurable metastatic disease ; ECOG performance status 01. local , locally advanced , pancreatic cancer ; prior systemic treatment metastatic pancreatic cancer ; &lt; =6 month since last adjuvant chemotherapy ; malignancy within last 5 year , except adequately treated cancer situ cervix , basal squamous cell skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>